硬化症-话题@MedSci

#硬化症#

413篇内容 | 2727人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1983134, encodeId=313a1983134a0, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=NEJM：苯丁酸钠-牛磺二醇治疗肌萎缩性侧索硬化症的疗效分析, objectType=article, longId=200187, objectId=cd2520018ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2520018ecd, replyNumber=0, likeNumber=78, createdTime=2021-05-04, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2520018ecd, moduleTitle=NEJM：苯丁酸钠-牛磺二醇治疗肌萎缩性侧索硬化症的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2520018ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983145, encodeId=492f19831453b, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=JNNP:遗传性和非遗传性肌萎缩侧索硬化症患者睡眠-觉醒障碍的研究, objectType=article, longId=202727, objectId=a93d202e2787, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a93d202e2787, replyNumber=0, likeNumber=73, createdTime=2021-02-10, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a93d202e2787, moduleTitle=JNNP:遗传性和非遗传性肌萎缩侧索硬化症患者睡眠-觉醒障碍的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a93d202e2787)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983102, encodeId=0c7a198310265, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症，获得美国FDA的快速通道指定, objectType=article, longId=189522, objectId=bca518952213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bca518952213, replyNumber=0, likeNumber=89, createdTime=2020-11-29, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bca518952213, moduleTitle=EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症，获得美国FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bca518952213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983111, encodeId=eab219831112c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=Semin Arthritis Rheu：系统性硬化症中的假瘤性钙质沉着, objectType=article, longId=192049, objectId=2e82192049a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e82192049a4, replyNumber=0, likeNumber=70, createdTime=2020-09-30, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e82192049a4, moduleTitle=Semin Arthritis Rheu：系统性硬化症中的假瘤性钙质沉着, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e82192049a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983140, encodeId=fe181983140a9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=Cell Biol Int：鼻内递送SDF-1α预处理的干细胞可改善杯多发性硬化症的再髓鞘化作用, objectType=article, longId=201547, objectId=8ab720154e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab720154e79, replyNumber=0, likeNumber=66, createdTime=2021-02-17, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab720154e79, moduleTitle=Cell Biol Int：鼻内递送SDF-1α预处理的干细胞可改善杯多发性硬化症的再髓鞘化作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab720154e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983098, encodeId=f6d319830984a, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=结节性硬化症相关肾血管平滑肌脂肪瘤诊疗与管理专家共识, objectType=article, longId=186831, objectId=fe6918683106, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe6918683106, replyNumber=0, likeNumber=17, createdTime=2020-08-11, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe6918683106, moduleTitle=结节性硬化症相关肾血管平滑肌脂肪瘤诊疗与管理专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe6918683106)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983126, encodeId=6452198312642, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=JAMA Neurol：继发性进行性多发性硬化症患者持续接受免疫治疗可降低残疾进展风险, objectType=article, longId=199174, objectId=50731991e4c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50731991e4c8, replyNumber=0, likeNumber=0, createdTime=2020-11-30, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50731991e4c8, moduleTitle=JAMA Neurol：继发性进行性多发性硬化症患者持续接受免疫治疗可降低残疾进展风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50731991e4c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983108, encodeId=c67919831081f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=FDA批准S1P受体调控剂ozanimod用于多发性硬化症药物, objectType=article, longId=191037, objectId=bf9e19103eb6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9e19103eb6, replyNumber=0, likeNumber=77, createdTime=2020-06-25, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9e19103eb6, moduleTitle=FDA批准S1P受体调控剂ozanimod用于多发性硬化症药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf9e19103eb6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983132, encodeId=d4971983132e2, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=NATURE：肠道微生物可以加剧多发性硬化症, objectType=article, longId=199966, objectId=f6d81999664a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6d81999664a, replyNumber=0, likeNumber=95, createdTime=2021-07-31, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6d81999664a, moduleTitle=NATURE：肠道微生物可以加剧多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6d81999664a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983115, encodeId=0f71198311538, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=Nat Immunol：多发性硬化症有了新的治疗选择, objectType=article, longId=192734, objectId=86b2192e34c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86b2192e34c8, replyNumber=0, likeNumber=120, createdTime=2020-04-26, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86b2192e34c8, moduleTitle=Nat Immunol：多发性硬化症有了新的治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86b2192e34c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983087, encodeId=052c198308e22, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, objectType=article, longId=183458, objectId=aa7d1834581c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7d1834581c, replyNumber=0, likeNumber=55, createdTime=2020-04-22, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7d1834581c, moduleTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7d1834581c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983104, encodeId=9b8a1983104ef, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=Ponesimod治疗成人多发性硬化症：强生已向美国FDA提交新药申请（NDA）, objectType=article, longId=190437, objectId=1dee19043e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dee19043e93, replyNumber=0, likeNumber=76, createdTime=2020-10-29, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dee19043e93, moduleTitle=Ponesimod治疗成人多发性硬化症：强生已向美国FDA提交新药申请（NDA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dee19043e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983131, encodeId=3cf41983131e0, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=Otol Neurotol：一个基于群体的耳硬化症发病率变化情况研究, objectType=article, longId=199873, objectId=47c81998e3cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47c81998e3cf, replyNumber=0, likeNumber=72, createdTime=2020-12-20, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47c81998e3cf, moduleTitle=Otol Neurotol：一个基于群体的耳硬化症发病率变化情况研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47c81998e3cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983105, encodeId=b6681983105e0, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=FDA准许开展IMS001治疗多发性硬化症的临床计划, objectType=article, longId=190580, objectId=83341905808f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83341905808f, replyNumber=0, likeNumber=109, createdTime=2020-07-09, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83341905808f, moduleTitle=FDA准许开展IMS001治疗多发性硬化症的临床计划, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83341905808f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983135, encodeId=47c419831352c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle= Lancet respirat med：托珠单抗治疗系统性硬化症的3期临床试验结果, objectType=article, longId=200216, objectId=67e12002166e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e12002166e, replyNumber=0, likeNumber=92, createdTime=2021-04-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e12002166e, moduleTitle= Lancet respirat med：托珠单抗治疗系统性硬化症的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e12002166e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983110, encodeId=3f3d19831105e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=J Rheumatol：极早期系统性硬化症的挑战：轻度和早期疾病的混合？, objectType=article, longId=191090, objectId=3561191090e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3561191090e0, replyNumber=0, likeNumber=68, createdTime=2021-01-05, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3561191090e0, moduleTitle=J Rheumatol：极早期系统性硬化症的挑战：轻度和早期疾病的混合？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3561191090e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983116, encodeId=1047198311689, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动, objectType=article, longId=192862, objectId=cb3a1928621f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3a1928621f, replyNumber=0, likeNumber=0, createdTime=2021-02-10, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3a1928621f, moduleTitle=实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb3a1928621f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983137, encodeId=5831198313ea1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=Sci Transl Med：反义寡核苷酸龙头Ionis管线药物，如何对抗痴呆症和肌萎缩侧索硬化症？, objectType=article, longId=200938, objectId=7d8720093855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d8720093855, replyNumber=0, likeNumber=78, createdTime=2021-06-25, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d8720093855, moduleTitle=Sci Transl Med：反义寡核苷酸龙头Ionis管线药物，如何对抗痴呆症和肌萎缩侧索硬化症？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d8720093855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983117, encodeId=677d198311e9c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=FDA批准Banner的BAFIERTAM（富马酸单甲酯），用于治疗多发性硬化症, objectType=article, longId=193382, objectId=b2ed193382f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ed193382f9, replyNumber=0, likeNumber=83, createdTime=2021-01-21, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ed193382f9, moduleTitle=FDA批准Banner的BAFIERTAM（富马酸单甲酯），用于治疗多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ed193382f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1983123, encodeId=ae68198312314, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, objectTitle=J Neurol Neurosur Ps：肌萎缩性侧索硬化症患者体重减轻的预后价值, objectType=article, longId=196898, objectId=981419689859, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=981419689859, replyNumber=0, likeNumber=88, createdTime=2021-04-12, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=981419689859, moduleTitle=J Neurol Neurosur Ps：肌萎缩性侧索硬化症患者体重减轻的预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=981419689859)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

硬化症

2020-05-29

30397604 (审核中...)

前往app查看评论内容

#硬化症#

NEJM：苯丁酸钠-牛磺二醇治疗肌萎缩性侧索硬化症的疗效分析

2021-05-04

30397604 (审核中...)

前往app查看评论内容

#硬化症#

JNNP:遗传性和非遗传性肌萎缩侧索硬化症患者睡眠-觉醒障碍的研究

2021-02-10

30397604 (审核中...)

前往app查看评论内容

#硬化症#

EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症，获得美国FDA的快速通道指定

2020-11-29

30397604 (审核中...)

前往app查看评论内容

#硬化症#

Semin Arthritis Rheu：系统性硬化症中的假瘤性钙质沉着

2020-09-30

30397604 (审核中...)

前往app查看评论内容

#硬化症#

Cell Biol Int：鼻内递送SDF-1α预处理的干细胞可改善杯多发性硬化症的再髓鞘化作用

2021-02-17

30397604 (审核中...)

前往app查看评论内容

#硬化症#

结节性硬化症相关肾血管平滑肌脂肪瘤诊疗与管理专家共识

2020-08-11

30397604 (审核中...)

前往app查看评论内容

#硬化症#

JAMA Neurol：继发性进行性多发性硬化症患者持续接受免疫治疗可降低残疾进展风险

2020-11-30

30397604 (审核中...)

前往app查看评论内容

#硬化症#

FDA批准S1P受体调控剂ozanimod用于多发性硬化症药物

2020-06-25

30397604 (审核中...)

前往app查看评论内容

#硬化症#

NATURE：肠道微生物可以加剧多发性硬化症

2021-07-31

30397604 (审核中...)

前往app查看评论内容

#硬化症#

Nat Immunol：多发性硬化症有了新的治疗选择

2020-04-26

30397604 (审核中...)

前往app查看评论内容

#硬化症#

美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？

2020-04-22

智慧医人 (审核中...)

前往app查看评论内容

#硬化症#

Ponesimod治疗成人多发性硬化症：强生已向美国FDA提交新药申请（NDA）

2020-10-29

30397604 (审核中...)

前往app查看评论内容

#硬化症#

Otol Neurotol：一个基于群体的耳硬化症发病率变化情况研究

2020-12-20

30397604 (审核中...)

前往app查看评论内容

#硬化症#

FDA准许开展IMS001治疗多发性硬化症的临床计划

2020-07-09

zhaojie88 (审核中...)

前往app查看评论内容

#硬化症#

Lancet respirat med：托珠单抗治疗系统性硬化症的3期临床试验结果

2021-04-14

30397604 (审核中...)

前往app查看评论内容

#硬化症#

J Rheumatol：极早期系统性硬化症的挑战：轻度和早期疾病的混合？

2021-01-05

30397604 (审核中...)

前往app查看评论内容

#硬化症#

实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动

2021-02-10

30397604 (审核中...)

前往app查看评论内容

#硬化症#

Sci Transl Med：反义寡核苷酸龙头Ionis管线药物，如何对抗痴呆症和肌萎缩侧索硬化症？

2021-06-25

30397604 (审核中...)

前往app查看评论内容

#硬化症#

FDA批准Banner的BAFIERTAM（富马酸单甲酯），用于治疗多发性硬化症

2021-01-21

30397604 (审核中...)

前往app查看评论内容

#硬化症#

J Neurol Neurosur Ps：肌萎缩性侧索硬化症患者体重减轻的预后价值

2021-04-12

科室
- - 订阅+
  - 更多科室
工具
服务